Supernus Pharmaceuticals(US:SUPN)2026-02-24 22:30Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million for the full year 2025, representing a 27% increase compared to the previous year [16] - For Q4 2025, total revenue was $211.6 million, a 21% increase year-over-year, and a 34% increase when excluding net product sales of Trokendi XR and Oxtellar XR [13][16] - GAAP net loss for the full year 2025 was $38.6 million, or a loss of $0.68 per diluted share, compared to a GAAP net earnings of $73.9 million, or $1.32 per diluted share in 2024 [17] - Adjusted operating earnings for the full year 2025 were $158.7 million, down from $183.7 million in 2024 [18] Business Line Data and Key Metrics Changes - Revenues from the four growth products (Qelbree, Proquarius, Zerzura, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales for its first year at $17.3 million [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [6] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [5] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by more than 150% [6] - GOCOVRI reached net sales of $146 million for the full year 2025, a 12% increase compared to 2024 [10] Company Strategy and Development Direction - The company aims to continue growing its core business while exploring corporate development opportunities to strengthen its position in the CNS market [11][76] - Supernus is focused on revenue-generating products and late-stage pipeline candidates, with a strategic emphasis on expanding its portfolio beyond CNS into areas like women's health [72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving total revenues of $840 million to $870 million for 2026, with expectations of $45 million to $70 million in net sales from ONAPGO [19] - The company anticipates combined R&D and SG&A expenses to range from $620 million to $650 million for 2026 [19] - Management highlighted the importance of maintaining a strong balance sheet with no debt, providing financial flexibility for future growth opportunities [18] Other Important Information - The company initiated a Phase IIb trial for SPN-820 and is progressing with ongoing trials for SPN-817, with data expected in 2027 [11][71] - Supernus has made significant investments in R&D and SG&A, with combined expenses reaching $591.8 million for the full year 2025 [16] Q&A Session Summary Question: ONAPGO supply and sales potential - Management confirmed that the current supplier can meet the $45 million-$70 million sales guidance for ONAPGO, with plans for continuity of supply into 2026 [21] Question: ONAPGO demand and patient enrollment - Management indicated that the current supplier will help clear the backlog and support new patient initiations, with ongoing processing of enrollment forms [28] Question: R&D prioritization post-Sage acquisition - Management stated that early-stage assets will undergo preclinical work, with prioritization based on market opportunity and ROI [29] Question: Zurzuvae commercial strategy - Management emphasized the need to build market awareness and confidence among physicians to drive prescriptions for Zurzuvae [59] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net for ONAPGO to be in the range of 20%-30%, typically higher in Q1 [66]